PowderJect Pharmaceuticals plc acquired in 2001 SBL Vaccin from Active Biotech, with an initial cash payment of 50 MUSD. According to the agreement, an additional payment of up to 10 MUSD will be received upon registration of the vaccine Dukoral in Europe.
Moreover, Active Biotech is entitled to a royalty payment on future sales of Dukoral in Europe, amounting to a maximum of 20 MUSD, based on yearly sales above the level of 40 MUSD.
Lund July 25, 2003
Active Biotech AB (publ)
Sven Andréasson
President & CEO
For further information about Active Biotech visit http://activebiotech.com.
Active Biotech
AB is a biotechnology company focusing on research in and development of pharmaceuticals. Active Biotech has a strong R&D portfolio and pipeline products with focus primarily on autoimmune/inflammatory diseases and cancer. Most advanced projects include orally administered small molecules with unique immunomodulatory properties that can be used to treat autoimmune and inflammatory diseases (SAIK), as well as a novel concept for use in cancer immunotherapy (TTS).
Active Biotech AB
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 20 50
e-mail info@activebiotech.com